Aura Biosciences, Inc. (NASDAQ:AURA) Insider Janet Jill Hopkins Sells 2,534 Shares of Stock

Aura Biosciences, Inc. (NASDAQ:AURA) insider Janet Jill Hopkins sold 2,534 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $7.75, for a total value of $19,638.50. Following the completion of the transaction, the insider now directly owns 269,794 shares of the company’s stock, valued at approximately $2,090,903.50. The trade was a 0.93 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Aura Biosciences Trading Down 3.8 %

NASDAQ AURA opened at $7.65 on Wednesday. The business’s 50-day moving average price is $8.07 and its two-hundred day moving average price is $8.76. Aura Biosciences, Inc. has a 12 month low of $6.63 and a 12 month high of $12.38. The firm has a market capitalization of $382.12 million, a PE ratio of -4.42 and a beta of 0.29.

Institutional Investors Weigh In On Aura Biosciences

A number of institutional investors have recently made changes to their positions in the stock. ProShare Advisors LLC bought a new stake in shares of Aura Biosciences in the 4th quarter valued at about $127,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Aura Biosciences by 27.7% in the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 136,516 shares of the company’s stock valued at $1,122,000 after buying an additional 29,618 shares during the last quarter. Ensign Peak Advisors Inc grew its position in shares of Aura Biosciences by 43.3% in the 4th quarter. Ensign Peak Advisors Inc now owns 390,695 shares of the company’s stock valued at $3,212,000 after buying an additional 118,000 shares during the last quarter. Deutsche Bank AG grew its position in shares of Aura Biosciences by 56.7% in the 4th quarter. Deutsche Bank AG now owns 44,085 shares of the company’s stock valued at $362,000 after buying an additional 15,951 shares during the last quarter. Finally, Bank of America Corp DE grew its position in shares of Aura Biosciences by 20.5% in the 4th quarter. Bank of America Corp DE now owns 51,286 shares of the company’s stock valued at $422,000 after buying an additional 8,709 shares during the last quarter. Institutional investors own 96.75% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 target price on shares of Aura Biosciences in a report on Thursday, November 14th. Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a report on Friday, January 31st. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $23.00.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.